Latest Conference Articles

New diagnostic tool iFR is less painful for heart patients than FFR.

Scott Solomon, MD, director of Noninvasive Cardiology at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, detailed study results for sacubitril/valsartan the first angiotensin receptor neprilysin inhibitor to be approved by the FDA for its indication.

Jay Edelberg, MD, PhD, discusses the alirocumab phase 3 trial results at ACC 2017. “The results demonstrated that genetics really teach us a lot,” he said, noting that the majority of high-risk patients were able to achieve their treatment goals with just the 75 mg dose.

In a large, long-term clinical trial evolocumab reduced heart risk.

In another major study comparing TAVR to surgery, outcomes were similar.

Details on why Pfizer pulled its PCSK9 inhibitor seen in SPIRE studies.

John Kelso, MD, Division of Allergy, Asthma, and Immunology, Scripps Clinic, San Diego, explained the concerns researchers had of administering vaccines to patients experiencing allergic reactions to those vaccines.

Amy Scurlock, MD, Arkansas Children's Hospital, reiterated that there is more at stake beyond the medical management of food allergies.

Amy Scurlock, MD, Arkansas Children's Hospital, and team conducted a study looking at walnut oral immunotherapy in children with tree nut allergies.

Luis Salmun, MD, VP, Medical Affairs, North America, DBV Technologies, discussed results from the Viaskin Peanut study and explained the patch could be a potential treatment for children with peanut allergies.

"Not only has it shown efficacy in atopic dermatitis, but dupilumab also has shown efficacy in related atopic dermatitis conditions such as asthma and nasal polyps," said Akinlade.

Bola Akinlade, MD, MBA, Executive Director, Regeneron Pharmaceuticals, discussed the results of the dupilumab study presented at AAAAI 2017.

Jared Ditkowsky, MD, SUNY Downstate, explained the connotations surrounding the development of a potential vaccine for Chlamydia trachomatis (C. trachomatis), the infection causing chlamydia - one of the most common bacterial sexually transmitted infections in the United States.

The phase 3b MUSCA trial reported positive results for mepolizumab.

Jared Ditkowsky, MD candidate, SUNY Downstate explained that many of the problems surrounding a potential chlamydia vaccine are immunologic in nature.

Do emergency department physicians follow the asthma care guidelines?

Researchers analyze walnut immunotherapy outcomes at 142 weeks.

Jay Jin, MD, PhD, Mayo Clinic, shared the results from his team's case series surrounding unexpected bradycardia effect from epinephrine administration.

Females were less likely to be compliant, a contradiction to previous research.

Anthony S. Fauci, MD, Director, National Institute of Allergy and Infectious Diseases (NIAID), shared with MD Magazine what the main theme would be in his keynote address at the AAAAI 2017 meeting in Atlanta, GA: emerging and reemerging infections, a perpetual challenge.

Only a small percentage of people who think they have a penicillin allergy actually do.

How safe are anti-inflammatory medications for children?

Mark S. Forshag, MD, MHA, with GSK, shared some of his team's next steps in advancing asthma care specifically with trying to keep things simple for the patients and their physicians.

Mark S. Forshag, MD, MHA, GSK, spoke with MD Magazine at AAAAI 2017 in Atlanta, GA, about the importance of eosinophils in treating severe asthma.

A chlamydia vaccine would cut infection rates, but cost millions.

The SQ HDM SLIT-tablet is already approved in Europe. Is the US next?

The study was conducted in patients with grass pollen-induced allergic rhinoconjunctivitis.

Would carrying a rescue inhaler correlate with better asthma control? That's what Sima J. Patel, DO and her team sought to investigate.

Trial results on novel multi-dose powder inhaler were revealed at AAAAI 2017.

Luz Fonacier, MD, Winthrop University Hospital, detailed the process of looking at eczema and contact dermatitis in an allergist's practice.